EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that John Maslowski, vice president, scientific affairs of Fibrocell Science will present on Tuesday, October 7 at 2:30 p.m. PDT at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California. Mr. Maslowski will discuss the company’s autologous fibroblast technology, and its therapeutic candidates in development focused on genetically-modified personalized biologics.
Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2014 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance cutting-edge research into cures. The Partnering Forum, held October 7 and 8 at the Estancia La Jolla Hotel, is the first and only partnering meeting of its kind dedicated solely to facilitating connections for the regenerative medicine and advanced therapies industry.
The meeting also features a nationally recognized Scientific Symposium, held October 9 at the Salk Institute for Biological Studies, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.
A live video webcast of all company presentations will be available at http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM’s website and the Fibrocell Science website shortly after the event.
Please visit http://stemcellmeetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors and media should contact Laura Parsons at email@example.com.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NASDAQ:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s lead orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). Working in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is genetically modifying autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and connective tissue disorders. Fibrocell is also pursuing medical applications for azficel-T—the Company’s proprietary autologous fibroblast technology—for restrictive burn scarring and vocal cord scarring. Both indications are currently in Phase II clinical trials. For additional information, visit www.fibrocellscience.com.